Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-0390 in Recurrent High-Grade Glioma
NCT05023551Phase 1Active, not recruiting
- Sponsor
- Sumitomo Pharma America
- Start
- Sep 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DSP-0390 in glioma, sponsored by Sumitomo Pharma America. Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events and Serious Adverse Events at 12 months, Maximum Tolerated Dose and/or Recommended Dose for Expansion at 28 days and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
DSP-0390
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05023551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023551.